| # | Drug | Count |
|---|---|---|
| 0 | OCRELIZUMAB | 1426 |
| 1 | ADALIMUMAB | 1314 |
| 2 | DUPILUMAB | 878 |
| 3 | ACETAMINOPHEN | 758 |
| 4 | NIRMATRELVIR AND RITONAVIR | 630 |
| 5 | PREDNISONE | 618 |
| 6 | ERGOCALCIFEROL | 510 |
| 7 | LENALIDOMIDE | 495 |
| 8 | ACETAMINOPHEN 500MG | 433 |
| 9 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 433 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | OCRELIZUMAB | 1426 | 0.0227 |
| 1 | ERGOCALCIFEROL | 510 | 0.0172 |
| 2 | TROPICAMIDE | 28 | 0.0171 |
| 3 | INFLIXIMAB-DYYB | 56 | 0.0163 |
| 4 | NIRMATRELVIR AND RITONAVIR | 630 | 0.0117 |
| 5 | LUTETIUM LU 177 DOTATATE | 65 | 0.0112 |
| 6 | NUSINERSEN | 75 | 0.0095 |
| 7 | CHLORPROMAZINE | 58 | 0.0092 |
| 8 | LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN | 121 | 0.0087 |
| 9 | REMDESIVIR | 90 | 0.0068 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 1953 |
| 1 | Corticosteroid [EPC] | 1276 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1099 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 969 |
| 4 | Interleukin-4 Receptor alpha Antagonist [EPC] | 878 |
| 5 | Thalidomide Analog [EPC] | 601 |
| 6 | Interleukin-23 Antagonist [EPC] | 512 |
| 7 | Provitamin D2 Compound [EPC] | 510 |
| 8 | Vitamin C [EPC] | 484 |
| 9 | Interleukin-17A Antagonist [EPC] | 454 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 133 | 0.1933 |
| 1 | Provitamin D2 Compound [EPC] | 510 | 0.0171 |
| 2 | Cyclooxygenase Inhibitor [EPC] | 1 | 0.0122 |
| 3 | Interleukin-17A Antagonist [EPC] | 454 | 0.0122 |
| 4 | CD38-directed Cytolytic Antibody [EPC] | 55 | 0.0094 |
| 5 | Radioligand Therapeutic Agent [EPC] | 121 | 0.0087 |
| 6 | Vitamin B6 Analog [EPC] | 3 | 0.0083 |
| 7 | Antisense Oligonucleotide [EPC] | 82 | 0.0069 |
| 8 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 90 | 0.0068 |
| 9 | Classical Complement Pathway Inhibitor [EPC] | 2 | 0.0062 |